Overexpression of High Mobility Group (HMG) B1 and B2 Proteins Directly Correlates with the Progression of Squamous Cell Carcinoma in Skin

REFERENCES

• Thomas J. O. HMG1 and 2: architectural DNA-binding proteins. Biochem Soc Trans 2001; 29: 395–401
   PubMed Web of Science ®Google Scholar
• Pallier C., Scaffidi P., Chopineau-Proust S., Agresti A., Nordmann P., Bianchi M. E., Marechal V. Association of chromatin proteins high mobility group box (HMGB) 1 and HMGB2 with mitotic chromosomes. Mol Biol Cell 2003; 3414–3426
   PubMed Web of Science ®Google Scholar
• Bustin M. Regulation of DNA-dependent activities by the functional motifs of the high-mobility-group chromosomal proteins. Mol Cell Biol 1999; 19(8)5237–5246
   PubMed Web of Science ®Google Scholar
• Landsman D., Bustin M. A signature for the HMG-1 box DNA-binding proteins. Bioessays 1993; 15: 539–46
   PubMed Web of Science ®Google Scholar
• Jain A., Akanchha S., Rajeswari M. R. Stabilization of purine motif DNA triplex by a tetrapeptide from the binding domain of HMGBI protein. Biochimie 2005; 87: 781–90
   PubMed Web of Science ®Google Scholar
• Muller S., Scaffidi P., Degryse B., Bonaldi T., Ronfani L., Agresti A., Beltrame M., Bianchi M. E. New EMBO members' review: the double life of HMGB1 chromatin protein: architectural factor and extracellular signal. EMBO J 2001; 20: 4337–40
   PubMed Web of Science ®Google Scholar
• Zappavigna V., Falciola L., Helmer-Citterich M., Mavilio F., Bianchi M. E. HMG1 interacts with HOX proteins and enhances their DNA binding and transcriptional activation. EMBO J 1996; 15: 4981–91
   PubMed Web of Science ®Google Scholar
• Boonyaratanakornkit V., Melvin V., Prendergast P., Altmann M., Ronfani L., Bianchi M. E., Taraseviciene L., Nordeen S. K., Allegretto E. A., Edwards D. P. High-mobility group chromatin proteins 1 and 2 functionally interact with steroid hormone receptors to enhance their DNA binding in vitro and transcriptional activity in mammalian cells. Mol Cell Biol 1998; 18: 4471–87
   PubMed Web of Science ®Google Scholar
• Uramoto H, Izumi H, Nagatani G, Ohmori H, Nagasue N, Ise T, Yoshida T, Yasumoto K, Kohno K. Physical interaction of tumour suppressor p53/p73 with CCAAT-binding transcription factor 2 (CTF2) and differential regulation of human high-mobility group 1 (HMG1) gene expression. Biochem J 2003; 371: 301–10
   PubMed Web of Science ®Google Scholar
• Chao J. C., Wan X. S., Engelsberg B. N., Rothblum L. I, Billings P. C. Intracellular distribution of HMG1, HMG2 and UBF change following treatment with cisplatin. Biochim Biophys Acta 1996; 1307: 213–219
   PubMed Web of Science ®Google Scholar
• McMurry M. T., Hernandez-Munain C., Lauzurica P., Krangel M. S. Enhancer control of local accessibility to V(D)J recombinase. Mol Cell Biol 1997; 17: 4553–61
   PubMed Web of Science ®Google Scholar
• Lotze M. T., Tracey K. J. High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal. Nat Rev Immunol 2005; 5: 331–42
   PubMed Web of Science ®Google Scholar
• Yang H., Wang H., Czura C. J., Tracey K. J. HMGB1 as a cytokine and therapeutic target. J Endotoxin Res 2002; 8: 469–72
   PubMedGoogle Scholar
• Taguchi A., Blood D. C., del Toro G., Canet A., Lee D. C., Qu W., Tanji N., Lu Y., Lalla E., Fu C., Hofmann M. A., Kislinger T., Ingram M., Lu A., Tanaka H., Hori O., Ogawa S., Stern D. M., Schmidt A. M. Blockade of RAGE-amphoterin signalling suppresses tumour growth and metastases. Nature 2000; 405: 354–60
   PubMed Web of Science ®Google Scholar
• Balasubramani M., Day B. W., Schoen R. E., Getzenberg R. H. Altered expression and localization of creatine kinase B, heterogeneous nuclear ribonucleoprotein F, and high mobility group box 1 protein in the nuclear matrix associated with colon cancer. Cancer Res, 66: 763–9
   PubMed Web of Science ®Google Scholar
• Kawahara N., Tanaka T., Yokomizo A., Nanri H., Ono M., Wada M., Kohno K., Takenaka K., Sugimachi K., Kuwano M. Enhanced coexpression of thioredoxin and high mobility group protein 1 genes in human hepatocellular carcinoma and the possible association with decreased sensitivity to cisplatin. Cancer Res 1996; 56: 5330–3
   PubMed Web of Science ®Google Scholar
• He Q., Liang C. H., Lippard S. J. Steroid hormones induce HMG1 overexpression and sensitize breast cancer cells to cisplatin and carboplatin. Proc Natl Acad Sci USA 2000; 97: 5768–72
   PubMed Web of Science ®Google Scholar
• Maeda S., Hikiba Y., Shibata W., Ohmae T., Yanai A., Ogura K., Yamada S., Omata M. Essential roles of high-mobility group box 1 in the development of murine colitis and colitis-associated cancer. Biochem Biophys Res Commun 2007; 360: 394–400
   PubMed Web of Science ®Google Scholar
• Pardo M., García A., Thomas B., Piñeiro A., Akoulitchev A., Dwek R. A., Zitzmann N. The characterization of the invasion phenotype of uveal melanoma tumour cells shows the presence of MUC18 and HMG-1 metastasis markers and leads to the identification of DJ-1 as a potential serum biomarker. Int J Cancer 2006; 119: 1014–22
   PubMed Web of Science ®Google Scholar
• Anon., American Cancer Society. Cancer Facts and Figure. New York 2003
   Google Scholar
• Rajeswari M. R., Singh D., Jain A., Ray R. Elevated levels of high-mobility-group chromosomal proteins, HMGA1, in murine skin carcinoma. Cancer Lett 2001; 173: 93–9
   PubMed Web of Science ®Google Scholar
• Rajeswari M. R., Jain A., Sharma A., Singh D., Jagannathan N. R., Sharma U., Degaonkar M. N. Evaluation of skin tumors by magnetic resonance imaging. Lab Invest 2003; 83: 1279–1283
   PubMed Web of Science ®Google Scholar
• Ghosh I., Chowdhury A. R., Rajeswari M. R., Datta K. Differential expression of Hyaluronic Acid Binding Protein 1 (HABP1)/P32/C1QBP during progression of epidermal carcinoma. Mol Cell Biochem 2004; 267: 133–9
   PubMed Web of Science ®Google Scholar
• Kawamori T., Uchiya N., Sugimura T., Wakabayashi K. Enhancement of colon carcinogenesis by prostaglandin E2 administration. Carcinogen 2003; 24: 985–90
   PubMed Web of Science ®Google Scholar
• Singh D., Rajeswari M. R. Enhanced Expression of HMG-Y proteins in Proliferating Tissues. Ind J Clin Biochem 2001; 16: 72–76
   Google Scholar
• Li J., Tang M. S., Liu B., Shi X., Huang C. A. Critical role of PI-3K/Akt/JNKs pathway in benzo[a]pyrene diol-epoxide (B[a]PDE)-induced AP-1 transactivation in mouse epidermal Cl41 cells. Oncogene 2004; 23: 3932–44
   PubMed Web of Science ®Google Scholar
• Bjelogrlic N. M., Mäkinen M., Stenbäck F., Vähäkangas K. Benzo[a]pyrene-7, 8-diol-9,10-epoxide-DNA adducts and increased p53 protein in mouse skin. Carcinogen 1994; 15: 771–4
   PubMed Web of Science ®Google Scholar
• Suh M., Ariese F., Small G. J., Jankowiak R., Hewer A., Phillips D. H. Formation and persistence of benzo[a]pyrene-DNA adducts in mouse epidermis in vivo: importance of adduct conformation. Carcinogen 1995; 16: 2561–9
   PubMed Web of Science ®Google Scholar
• Humble M. C., Trempus C. S., Spalding J. W., Cannon R. E., Tennant R. W. Biological, cellular, and molecular characteristics of an inducible transgenic skin tumor model: a review. Oncogene 2005; 24: 8217–28
   PubMed Web of Science ®Google Scholar
• Li D., Wang L. E., Chang P., E.l-Naggar A. K., Sturgis E. M., Wei Q. In vitro benzo[a]pyrene diol epoxide-induced DNA adducts and risk of squamous cell carcinoma of head and neck. Cancer Res 2007; 67: 5628–34
   PubMed Web of Science ®Google Scholar
• Hays F. A., Teegarden A., Jones Z. J., Harms M., Raup D., Watson J., Cavaliere E, Ho P. S. How sequence defines structure: a crystallographic map of DNA structure and conformation. Proc Natl Acad Sci USA 2005; 102: 7157–62
   PubMed Web of Science ®Google Scholar
• Bhana S., Lloyd D. R. The role of p53 in DNA damage-mediated cytotoxicity overrides its ability to regulate nucleotide excision repair in human fibroblasts. Mutagenesis 2008; 23: 43–50
   PubMed Web of Science ®Google Scholar
• Rajeswari M. R., Jain A. High-mobility-group chromosomal proteins, HMGA1 as potential tumor markers. Current Sci 2002; 82: 838–844
   Web of Science ®Google Scholar
• Hock R., Furusawa T., Ueda T., Bustin M. HMG chromosomal proteins in development and disease. Trends Cell Biol 2007; 17: 72–9
   PubMed Web of Science ®Google Scholar
• Raucci A., Palumbo R., Bianchi M. E. HMGB1: a signal of necrosis. Autoimmunity 2007; 40: 285–289
   PubMed Web of Science ®Google Scholar
• Scaffidi P., Misteli T., Bianchi M. E. Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature 2002; 418: 191–195
   PubMed Web of Science ®Google Scholar
• Bustin M. At the crossroads of necrosis and apoptosis: signaling to multiple cellular targets by HMGB1. Sci STKE 2002; PE39
   Google Scholar
• Ito N., DeMarco R. A., Mailliard R. B., Han J., Rabinowich H., Kalinski P., Stolz D. B., Lotze M. T. Cytolytic cells induce HMGB1 release from melanoma cell lines. J Leukoc Biol 2007; 81: 75–83
   PubMed Web of Science ®Google Scholar
• Akaike H., Kono K., Sugai H., Takahashi A., Mimura K., Kawaguchi Y., Fujii H. Expression of high mobility group box chromosomal protein-1 (HMGB-1) in gastric cancer. Anticancer Res 2007; 27: 449–57
   PubMed Web of Science ®Google Scholar
• Poser I., Golob M., Buettner R., Bosserhoff A. K. Upregulation of HMG1 leads to melanoma inhibitory activity expression in malignant melanoma cells and contributes to their malignancy phenotype. Mol Cell Biol 2003; 23: 2991–8
   PubMed Web of Science ®Google Scholar
• Rovere-Querini P., Capobianco A., Scaffidi P., Valentinis B., Catalanotti F., Giazzon M., Dumitriu I. E., Muller S., Iannacone M., Traversari C., Bianchi M. E., Manfredi A. A. HMGB1 is an endogenous immune adjuvant released by necrotic cells. EMBO Rep 2004; 5: 825–830
   PubMed Web of Science ®Google Scholar
• Riuzzi F., Sorci G., Donato R. RAGE expression in rhabdomyosarcoma cells results in myogenic differentiation and reduced proliferation, migration, invasiveness, and tumor growth. Am J Pathol 2007; 171: 947–61
   PubMed Web of Science ®Google Scholar
• Taguchi A., Blood D. C., del Toro G., Canet A., Lee D. C., Qu W., Tanji N., Lu Y., Lalla E., Fu C., Hofmann M. A., Kislinger T., Ingram M., Lu A., Tanaka H., Hori O., Ogawa S., Stern D. M., Schmidt A. M. Blockade of RAGE-amphoterin signalling suppresses tumour growth and metastases. Nature 2000; 405: 354–60
   PubMed Web of Science ®Google Scholar
• Sasahira T., Kirita T., Bhawal U. K., Ikeda M., Nagasawa A., Yamamoto K., Kuniyasu H. The expression of receptor for advanced glycation end products is associated with angiogenesis in human oral squamous cell carcinoma. Virchows Arch 2007; 450: 287–95
   PubMed Web of Science ®Google Scholar
• Palumbo R., Galvez B. G., Pusterla T., De Marchis F., Cossu G., Marcu K. B., Bianchi M. E. Cells migrating to sites of tissue damage in response to the danger signal HMGB1 require NF-{kappa}B activation. J Cell Biol 2007; 179: 33–40
   PubMed Web of Science ®Google Scholar
• Andersson U., Erlandsson-Harris H., Yang H., Tracey K. J. HMGB1 as a DNA-binding cytokine. J Leukoc Biol 2002; 72: 1084–91
   PubMed Web of Science ®Google Scholar
• Ellerman J. E., Brown C. K., de Vera M., Zeh H. J., Billiar T., Rubartelli A., Lotze M. T. Masquerader: high mobility group box-1 and cancer. Clin Cancer Res 2007; 13: 2836–48
   PubMed Web of Science ®Google Scholar
• Lotze M. T., DeMarco R. A. Dealing with death: HMGB1 as a novel target for cancer therapy. Curr Opin Investig Drugs 2003; 4: 1405–1409
   PubMedGoogle Scholar